Yumanity is combining operations with Proteostasis Therapeutics, a deal that gives the biotech a public listing for its neurodegenerative disorder compounds including a Parkinson’s disease drug candidate in early-stage clinical development.
According to terms of the merger agreement announced Monday, Proteostasis (NASDAQ: PTI) will acquire all outstanding shares of Yumanity in exchange for new shares of PTI common stock. When the deal closes, Yumanity shareholders will own about 67.5 percent of the combined company while Proteostasis shareholders will own the remaining 32.5 percent. The combined company will be based at Yumanity’s Boston headquarters and will be led by Richard Peters,... Read more »
UNDERWRITERS AND PARTNERS
Author: Frank Vinluan
Date : 2020-08-24T18:56:29.000Z